ULTI Ultimovacs

Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation

Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation

Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its fourth quarter 2024 results, on Friday, January 31, 2025.

The presentation can be followed as a live webcast accessed through a link on at 09:00 CET on Friday, January 31, 2025. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through the webcast. Note that the webcast presentation has been rescheduled from February 13, 2025, due to the ongoing business combination with Zelluna Immunotherapy AS, in order to fulfill regulatory requirements associated with this process.

The report and presentation will be available on the company website from 07:00 CET the same day.

For further information, please see or contact:

Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASA

Email:

Phone:



EN
27/01/2025

Underlying

ULTIUltimovacs

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultimovacs

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
7h / 56m 7h / 56m 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provi...

Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results today. Conference call and webcast scheduled for January 31, 2025, at 09:00 (CET). Link to webcast . Fourth Quarter 2024 Business Update Highlights On December 17, 2024, Ultimovacs announced an agreement to combine its business with Zelluna Immunotherapy AS and the intention to launch a fully...

8h / 54m 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast pres...

Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its fourth quarter 2024 results, on Friday, January 31, 2025. The presentation can be followed as a live webcast accessed through a link on at 09:00 CET on Friday, January 31, 2025. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through...

January 27, 2025 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA: Notification of major holdings

Ultimovacs ASA: Notification of major holdings Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the "Company") on (i) 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS (the "Business Combination") and the fully committed private placement with gross proceeds of approx. NOK 51.7 million (the "Private Placement") and (ii) today on 9 January 2025 regarding the approval by an extraordinary general meeting of the Company (the "EGM") of relevant resolutions related to the Business Com...

January 9, 2025 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA – Extraordinary General Meeting held on January 9, 2025

Ultimovacs ASA – Extraordinary General Meeting held on January 9, 2025 Oslo, January 9, 2025: Ultimovacs ASA held its extraordinary general meeting today January 9, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and available at the company’s website. For further information, please see or contact: Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA Email: Phone: Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASA Email: Phone: Attachment

January 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch